Lifecore BiomedicalLFCR
LFCR
About: Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Employees: 406
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
262% more call options, than puts
Call options by funds: $76K | Put options by funds: $21K
83% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 18
16% more capital invested
Capital invested by funds: $190M [Q1] → $220M (+$30.2M) [Q2]
0.23% more ownership
Funds ownership: 66.19% [Q1] → 66.42% (+0.23%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
2% less funds holding
Funds holding: 86 [Q1] → 84 (-2) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for LFCR.
Financial journalist opinion
Based on 7 articles about LFCR published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
LIFECORE ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options
Neutral
Seeking Alpha
2 weeks ago
Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript
Universal Electronics Inc. (UEIC) Q4 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Paul Josephs - President, CEO & Director Ryan D. Lake - EVP & CFO Conference Call Participants Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Maxwell Andrew Smock - William Blair & Company L.L.C.
Positive
The Motley Fool
2 weeks ago
Lifecore (LFCR) Q4 Revenue Beats 3%
Lifecore Biomedical (LFCR 0.78%), a contract development and manufacturing company focused on sterile injectable pharmaceuticals and hyaluronic acid (HA) products, reported fiscal fourth-quarter 2025 results on August 7, 2025. The company reported GAAP revenue of $36.4 million in Q4 FY2025, exceeding the analyst estimate of $35.4 million (GAAP), and narrowed its GAAP loss per share to $(0.06), beating the forecast $(0.10) GAAP loss.
Neutral
Zacks Investment Research
2 weeks ago
Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates
Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.15 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
-- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance ; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional Area of Strength in Ophthalmic Therapeutics -- -- Improved Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced its financial results for the fourth quarter and fiscal year 2025.
Positive
Seeking Alpha
2 weeks ago
Laughing Water Capital's Top 5 Positions For Q2 2025
Lifecore Biomedical is positioned for margin expansion and likely acquisition, supported by industry trends and potential M&A multiples above current share price. NextNav is favorably placed for FCC spectrum approval, with strong national security tailwinds and potential for significant share price appreciation upon monetization. SECURE Waste Infrastructure offers downside protection, recurring cash flows, aggressive buybacks, and potential for 30-40% equity CAGR if valuation re-rates.
Neutral
GlobeNewsWire
3 weeks ago
Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025
CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and fiscal year 2025 on Thursday, August 7, 2025, after market close.
Neutral
GlobeNewsWire
1 month ago
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHASKA, Minn., July 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on July 11, 2025, the Lifecore compensation committee approved grants under Lifecore's Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate of 6,338 shares of its common stock and stock options for an aggregate of 29,575 shares of common stock to three newly hired employees. The awards will be granted on July 11, 2025, or the first day of employment, whichever is later, pursuant to offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.
Neutral
Seeking Alpha
1 month ago
Stock Picks From Seeking Alpha's June 2025 New Analysts
June saw a record number of 48 new Seeking Alpha analysts, each bringing fresh stock ideas and unique backgrounds to the platform. Analysts provided ratings from Sell to Buy, with detailed justifications based on market trends, company fundamentals, and sector-specific challenges. Key investment theses include bullish views on Alphabet, TSM, AppLovin, and Rolls-Royce, a bearish call Samsara, and a neutral stance on SoundHound AI.
Positive
Seeking Alpha
2 months ago
Lifecore Biomedical: Inflecting Financials Over Next 3 Years
Lifecore Biomedical is emerging from a challenging restructuring and is now a pure play CDMO with new management, an improved balance sheet, expanded capacity, and a solid business plan. Industry dynamics and recent M&A suggest a decent chance of a near-term acquisition, potentially valuing LFCR at 2x its current price. LFCR's growth runway and customer stickiness support its premium valuation, but risks include easing capacity constraints and an uncertain exit multiple.
Charts implemented using Lightweight Charts™